TP53 and B-cell chronic lymphocytic leukemia: Major mutations in CLL affect many cellular components including inflammatory receptors (e.g., MYD88), kinases such as MAPK (e.g., BRAF), NF-kB-related molecules (e.g., BIRC3), transcription (e.g., EGR2 and NOTCH1) and splicing factors (e.g., SF3B1), DNA damage and cell cycle control factors (e.g., ATM and TP53) [6].